Skip to main content Skip to navigation
BV421 Mouse Anti-C3/C3b/iC3b
Alert icon
If you're planning to order more than 10 BD OptiBuild™ Reagents, please contact your local sales representative to place this order. Contact Us #
BV421 Mouse Anti-C3/C3b/iC3b
Flow cytometric analysis of Human C3/C3b/iC3b deposition on Human peripheral blood lymphocytes. Human peripheral blood mononuclear cells were treated with either Purified NA/LE Mouse Anti-Human CD3 antibody (Cat. No. 555336, Left Plot) or Purified NA/LE Mouse IgG2a, κ Isotype Control (Cat. No. 554645: Right Plot) and were incubated with Human serum (as a source of Complement) for 30 min at 37°C. After washing, the cells were stained with either BD Horizon™ BV421 Mouse IgG1, κ Isotype Control (Cat. No. 562438; dotted line histograms) or BD OptiBuild™ Mouse Anti-C3/C3b/iC3b antibody (Cat. No. 752718; solid line histograms) at 0.5 µg/test. The fluorescence histograms showing the deposition of human C3/C3b/iC3b were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software. Data shown on this Technical Data Sheet are not lot specific.
BV421 Mouse Anti-C3/C3b/iC3b
Flow cytometric analysis of Mouse C3/C3b/iC3b deposition on C57BL/6 Mouse thymocytes. Thymocytes from a C57BL/6 Mouse were treated with either Purified NA/LE Rat Anti-Mouse CD90.2 antibody (Cat. No. 553008, Left Plot) or Purified NA/LE Rat IgG2b, κ Isotype Control (Cat. No. 555845, Right Plot) and were incubated with Mouse serum (as a source of Complement) for 20 min at 4°C. After washing, the cells were stained with either BD Horizon™ BV421 Mouse IgG1, κ Isotype Control (Cat. No. 562438; dotted line histograms) or BD OptiBuild™ Mouse Anti-C3/C3b/iC3b antibody (Cat. No. 752718; solid line histograms) at 0.5 µg/test. The fluorescence histograms showing the deposition of Mouse C3/C3b/iC3b were derived from gated events with the forward and side light-scatter characteristics of viable thymocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software. Data shown on this Technical Data Sheet are not lot specific.
Flow cytometric analysis of Human C3/C3b/iC3b deposition on Human peripheral blood lymphocytes. Human peripheral blood mononuclear cells were treated with either Purified NA/LE Mouse Anti-Human CD3 antibody (Cat. No. 555336, Left Plot) or Purified NA/LE Mouse IgG2a, κ Isotype Control (Cat. No. 554645: Right Plot) and were incubated with Human serum (as a source of Complement) for 30 min at 37°C. After washing, the cells were stained with either BD Horizon™ BV421 Mouse IgG1, κ Isotype Control (Cat. No. 562438; dotted line histograms) or BD OptiBuild™ Mouse Anti-C3/C3b/iC3b antibody (Cat. No. 752718; solid line histograms) at 0.5 µg/test. The fluorescence histograms showing the deposition of human C3/C3b/iC3b were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software. Data shown on this Technical Data Sheet are not lot specific.
Flow cytometric analysis of Mouse C3/C3b/iC3b deposition on C57BL/6 Mouse thymocytes. Thymocytes from a C57BL/6 Mouse were treated with either Purified NA/LE Rat Anti-Mouse CD90.2 antibody (Cat. No. 553008, Left Plot) or Purified NA/LE Rat IgG2b, κ Isotype Control (Cat. No. 555845, Right Plot) and were incubated with Mouse serum (as a source of Complement) for 20 min at 4°C. After washing, the cells were stained with either BD Horizon™ BV421 Mouse IgG1, κ Isotype Control (Cat. No. 562438; dotted line histograms) or BD OptiBuild™ Mouse Anti-C3/C3b/iC3b antibody (Cat. No. 752718; solid line histograms) at 0.5 µg/test. The fluorescence histograms showing the deposition of Mouse C3/C3b/iC3b were derived from gated events with the forward and side light-scatter characteristics of viable thymocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software. Data shown on this Technical Data Sheet are not lot specific.
Product Details
Down Arrow Up Arrow


BD OptiBuild™
Complement Component 3; C3; C3b; C3bi; iC3b
Human,Mouse (Tested in Development)
Mouse IgG1, κ
Human C3
Flow cytometry (Qualified)
0.2 mg/ml
718, 12266
Aqueous buffered solution containing ≤0.09% sodium azide.
RUO


Preparation And Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.

Recommended Assay Procedures

BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation).  When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells.   However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls.  It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.

For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime BD Horizon Brilliant dyes are used in a multicolor flow cytometry panel.  Fluorescent dye interactions may cause staining artifacts which may affect data interpretation.  The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. When BD Horizon Brilliant Stain Buffer is used in in the multicolor panel, it should also be used in the corresponding compensation controls for all dyes to achieve the most accurate compensation. For the most accurate compensation, compensation controls created with either cells or beads should be exposed to BD Horizon Brilliant Stain Buffer for the same length of time as the corresponding multicolor panel. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).

Product Notices

  1. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
  2. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  3. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
  4. An isotype control should be used at the same concentration as the antibody of interest.
  5. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
  6. Researchers should determine the optimal concentration of this reagent for their individual applications.
  7. BD Horizon Brilliant Violet 421 is covered by one or more of the following US patents: 8,158,444; 8,362,193; 8,575,303; 8,354,239.
  8. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
  9. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
  10. Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
  11. For U.S. patents that may apply, see bd.com/patents.
752718 Rev. 2
Antibody Details
Down Arrow Up Arrow
6C9

The 6C9 monoclonal antibody specifically recognizes human and mouse Complement component 3 (C3) and its multifunctional C3b and iC3b fragments. C3 is a ~190 kDa plasma glycoprotein that functions as a key component of the classical, alternative and lectin complement activation pathways. Active C3 fragments participate in innate and adaptive immune responses that eliminate pathogens, dying cells, and immune complexes from the body. C3 is produced by hepatocytes, mast cells, and leucocytes including some monocytes, macrophages, dendritic cells (DC), and T cells. As a result of complement activation, eg, initiated by an antigen-antibody immune complex in the classical pathway, biologically active C3b fragments can be cleaved from C3 by enzymatic C3 convertases. C3b can function as an opsonin by binding covalently via its reactive thioester to the surfaces of target cells, including microbes. C3b can also bind to antigen-antibody immune complexes. Macrophages and neutrophils can recognize and bind to C3b by their complement receptors, such as Complement Receptor 1 (CR1, CD35), which enhances their phagocytosis of C3b-bound target cells or immune complexes. Opsonization of target surfaces, including the cell surfaces of pathogenic organisms, infected or tumor cells, through C3b deposition is central to all three pathways of complement activation during innate or adaptive immune responses. C3b can also associate with other components of the complement system to form a C5 convertase. This complex cleaves C5 into the C5a anaphylatoxin and C5b which initiates formation of the of the cytolytic membrane attack complex (MAC) that can form holes in target cell membranes leading to cell lysis. C3b can be further cleaved into iC3b by factor I protease and its cofactors. The iC3b fragment serves as a ligand for engaging lymphoid and phagocytic cells via various receptors including CR2 (CD21), CR3 (CD11b/CD18), CR4 (CD11c/CD18), and CRIg.

The antibody was conjugated to BD Horizon BV421 which is part of the BD Horizon Brilliant™ Violet family of dyes. With an Ex Max near 407 nm and Em Max near 421 nm, BD Horizon BV421 can be excited by the violet laser (405 nm) and detected with a 450/50 nm filter. BD Horizon BV421 conjugates are very bright, often exhibiting a 10 fold improvement in brightness compared to Pacific Blue™ conjugates. Due to nearly identical excitation and emission properties but different spillover characteristics, BD Horizon BV421, Pacific Blue™, and BD Horizon V450 cannot be used simultaneously.

752718 Rev. 2
Format Details
Down Arrow Up Arrow
BV421
The BD Horizon Brilliant Violet™ 421 (BV421) Dye is part of the BD Horizon Brilliant Violet™ family of dyes. This polymer-technology based dye has an excitation maximum (Ex Max) of 407-nm and an emission maximum (Em Max) at 423-nm. Driven by BD innovation, BV421 is designed to be excited by the violet laser (405-nm) and detected using an optical filter centered near 420-nm (e.g., a 431/28-nm or 450/50-nm bandpass filter). BV421 is an ideal alternative for V450 as it is approximately ten times brighter with less spillover into the BV510/V500 detector. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
altImg
BV421
Violet 405 nm
407 nm
423 nm
752718 Rev.2
Citations & References
Down Arrow Up Arrow

Development References (5)

  1. Colonna L, Parry GC, Panicker S, Elkon KB. Uncoupling complement C1s activation from C1q binding in apoptotic cell phagocytosis and immunosuppressive capacity.. Clin Immunol. 2016; 163:84-90. (Clone-specific: Flow cytometry). View Reference
  2. Dufloo J, Guivel-Benhassine F, Buchrieser J, et al. Anti-HIV-1 antibodies trigger non-lytic complement deposition on infected cells.. EMBO Rep. 2020; 21(2):e49351. (Clone-specific: Flow cytometry). View Reference
  3. Lubbers R, van Essen MF, van Kooten C, Trouw LA. Production of complement components by cells of the immune system.. Clin Exp Immunol. 2017; 188(2):183-194. (Biology). View Reference
  4. Shi J, Rose EL, Singh A, et al. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins.. Blood. 2014; 123(26):4015-22. (Clone-specific: Flow cytometry). View Reference
  5. Sun D, Zhang M, Liu G, et al. Real-Time Imaging of Interactions of Neutrophils with Cryptococcus neoformans Demonstrates a Crucial Role of Complement C5a-C5aR Signaling.. Infect Immun. 2016; 84(1):216-29. (Clone-specific: Flow cytometry). View Reference
View All (5) View Less
752718 Rev. 2

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.